In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.


  • Debbie Shawcross (Moderator)
  • Rajiv Jalan (Faculty)
  • Sara Montagnese (Faculty)
  • Elliot Tapper (Faculty)

This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership